Candel Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
CADL$9.49+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| YEAR ENDED DECEMBER 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Research and development service revenue, related party | $— | $125 |
| Operating expenses: | ||
| Research and development | 24,506 | 20,787 |
| General and administrative | 13,885 | 14,060 |
| Total operating expenses | 38,391 | 34,847 |
| Loss from operations | (38,391) | (34,722) |
| Other income (expense): | ||
| Grant income | — | 48 |
| Interest income | 2,081 | 1,218 |
| Interest expense | (2,595) | (1,708) |
| Change in fair value of warrant liability | 966 | 16,370 |
| Total other income (expense), net | 452 | 15,928 |
| Net loss and comprehensive loss | $(37,939) | $(18,794) |
| Net loss per share, basic and diluted | $(1.31) | $(0.65) |
| Weighted-average common shares outstanding, basic and diluted | 28,935,289 | 28,823,480 |
Candel ThErapeutics, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.